Author

Andreas Hagenow

OpenAlex ID: A5113665610

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

2018 · Adrian F Hernandez, Jennifer B Green, et al. · The Lancet · 1,822

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 216

Global Variations in Heart Failure Etiology, Management, and Outcomes

2023 · G-CHF Investigators, Mariela Rasmussen, et al. · JAMA · 176

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction

2021 · Burkert Pieske, Rolf Wachter, et al. · JAMA · 163

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 105

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

2020 · Carolyn S. P. Lam, Anna Giczewska, et al. · JAMA Cardiology · 85

Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study

2024 · Kausik K Ray, Carlos Aguiar, et al. · European Journal of Preventive Cardiology · 79

Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial

2020 · Tiny Jaarsma, Leonie Klompstra, et al. · European Journal of Heart Failure · 78

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

2025 · Faiez Zannad, Christopher M O'Connor, et al. · The Lancet · 50

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

2022 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 38

Multivariate and multidimensional analysis of cardiovascular oscillations in patients with heart failure

2006 · Andreas Voss, Rico Schroeder, et al. · Biomedizinische Technik/Biomedical Engineering · 9

Changes Over Time in Patient-Reported Outcomes in Patients with Heart Failure

2023 · Tiny Jaarsma, Naoko P. Kato, et al. · ESC Heart Failure · 8

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease

2025 · Stephen J. Nicholls, Donna H. Ryan, et al. · JAMA Cardiology · 6

Efficacy and Safety of Semaglutide According to Frailty Status

2026 · John W. Ostrominski, Jorge Plutzky, et al. · JAMA Cardiology

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

2023 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care

Works count: 15

Citation count: 2,834

H-index: 10

I10-index: 10